Por favor, use este identificador para citar o enlazar este Item:http://hdl.handle.net/20.500.12105/20271
Título
Real-world treatment practice in patients with advanced melanoma in the era before ipilimumab: results from the IMAGE study
Autor(es)
Fecha de publicación
2016-07
Cita
Middleton MR, Dalle S, Claveau J, Mut Sanchís P, Hallmeyer S, Plantin P, et al. Real-world treatment practice in patients with advanced melanoma in the era before ipilimumab: results from the IMAGE study. Cancer Med. 2016 Jul;5(7):1436-43. Epub 2016 Apr 26.
Idioma
Inglés
Tipo de documento
research article
Resumen
The therapeutic landscape for advanced melanoma has recently been transformed by several novel agents (immune checkpoint inhibitors and molecular-targeted agents). The prospective, multi-site, observational study IMAGE (ipilimumab: management of advanced melanoma in real practice) included a retrospective cohort to describe real-world treatment prior to approval of the immune checkpoint inhibitor ipilimumab. This retrospective cohort of patients, who started second-line/subsequent treatment (index therapy) for advanced melanoma within 3 years before ipilimumab approval, was selected randomly by chart review. Collected data included treatment history, patient outcomes, and healthcare resource utilization. All patients had >= 1 year of follow-up data. This analysis included 177 patients from Europe (69%) and North America (31%). The most common index therapies (used alone or in combination) were fotemustine (23%), dacarbazine (21%), temozolomide (14%), and platinum-based chemotherapy (14%). Most patients (89%) discontinued index treatment during the study period; the most common reason was disease progression (59%). Among patients with tumor assessment (153/177; 86%), 2% had complete response, 5% had partial response, and 12% had stable disease on last tumor assessment. At 1-year study follow-up, median progression-free survival was 2.6 months (95% confidence interval [CI], 2.1-2.9) and median overall survival was 8.8 months (95% CI, 6.5-9.7). During follow-up, 95% of the patients had healthcare visits for advanced melanoma, 74% of whom were hospitalized or admitted to a hospice facility. These results provide insights into patient care with advanced melanoma in the era before ipilimumab and may serve as a benchmark for new agents in future real-world studies.
Palabras clave
Advanced melanoma | Ipilimumab | Observational study | Real-world treatment practice | Retrospective
MESH
Aged, 80 and over | Aged | Retreatment | Young Adult | Adult | Humans | Adolescent | Antineoplastic Combined Chemotherapy Protocols | Antineoplastic Agents | Melanoma | Middle Aged | Neoplasm Staging | Male | Molecular Targeted Therapy | Neoplasm Metastasis | Female | Ipilimumab | Treatment Outcome | Survival Analysis | Comorbidity | Retrospective Studies
DECS
Resultado del Tratamiento | Comorbilidad | Ipilimumab | Análisis de Supervivencia | Femenino | Estadificación de Neoplasias | Metástasis de la Neoplasia | Adolescente | Masculino | Antineoplásicos | Humanos | Melanoma | Persona de Mediana Edad | Adulto Joven | Protocolos de Quimioterapia Combinada Antineoplásica | Anciano | Anciano de 80 o más Años | Terapia Molecular Dirigida | Estudios Retrospectivos | Adulto | Retratamiento
Versión en línea
DOI
Aparece en las colecciones
Acceso a texto completo